Introduction {#S0001}
============

Antibiotics are the most commonly prescribed drugs in hospitals. This intensive and frequent use favors the selection of resistant strains, which can cause serious infections in patients. Resistance leads to ineffective clinical treatment in the case of some bacterial species, increasing the problem of microbial resistance to antimicrobials.[@CIT0001] Resistance such as extended-spectrum β-lactamase producing (ESBL), *Klebsiella pneumoniae* carbapenemase (KPC) producing, and methicillin-resistant *Staphylococcus aureus* (MRSA) lead to therapeutic failure, high treatment cost, and patient death (high mortality).[@CIT0002],[@CIT0003] MRSA strains were the most prevalent pathogens, contributed to 56% of nosocomial and community infections, and were the most common multidrug-resistant microorganisms in hospitals.[@CIT0004] A study published in 2016 estimated a rate of 10 million deaths due to antimicrobial-resistant microorganisms in 2050.[@CIT0001] Therefore, there is a necessity to discover new treatment options.

Statins are known for their antihyperlipidemic effects by competitively inhibiting the enzyme HMG-CoA reductase, decreasing cholesterol biosynthesis.[@CIT0005] This drug is also known to present pleiotropic effects, such as anti-inflammatory and antithrombotic.[@CIT0006],[@CIT0007] Furthermore, in 2008 a study that described the antibacterial effects of statins found that simvastatin and fluvastatin were active against MRSA and Vancomycin-resistant *Enterococcus* (VRE) strains.[@CIT0008]

Metals have been used since ancient times as antibacterial agents and present different properties and spectra of action. Among the metals, silver is one of the most commonly used due to its efficiency as an antimicrobial and low toxicity, being impregnated in utensils and materials used in medicine.[@CIT0009]

With the advent of nanotechnology in the medical area, silver nanoparticles (AgNP) have become widely studied for their antimicrobial action, including against multidrug-resistant bacteria.[@CIT0010]--[@CIT0015] AgNP are interesting when compared to silver ions due to their small size and high superficial area, which, in turn, improves their ability to react with multiple molecules. This feature leads to an ultra-large surface area per volume, where a large proportion of atoms are in immediate contact with the environment and readily available for reactions.[@CIT0016]--[@CIT0020] Biological synthesis is interesting when compared with chemical and physical syntheses because it not uses toxic solvents, being an environmentally friendly technology and low-cost.[@CIT0021],[@CIT0022] Therefore, metallic nanoparticles produced by biogenic synthesis with biomolecules and proteins hold up the stabilization of nanosystems.[@CIT0021],[@CIT0023],[@CIT0024]

Despite the well-known antibacterial activity of silver, silver-resistant *Escherichia coli* was isolated and identified from a burn wound treated with silver nitrate.[@CIT0025] In addition, resistant microorganisms were isolated from different environments with a natural occurrence of silver, such as in mines and marine water,[@CIT0019],[@CIT0026],[@CIT0027] and, a recent study showed how fast *E. coli* develops resistance after contact with AgNP for several generations.[@CIT0028]

To avoid this problem, according to the literature, combining AgNP~bio~ with other antibiotic compounds is a promising new strategy to control resistant bacterial infections, since it is effective against multidrug-resistant bacteria and the combination decreases the emergence of new antimicrobial resistance.[@CIT0012],[@CIT0014],[@CIT0029]

The combination of nanoparticles with antibiotics could have great potential in the control of multidrug-resistant microorganisms. This combination results in an improved bactericidal effect compared to drugs alone.[@CIT0020] AgNP has demonstrated different antimicrobial interactions depending on the microorganism strain and compound tested.[@CIT0030] Ampicillin, kanamycin, chloramphenicol, and erythromycin showed increased antibacterial activity when combined with AgNP against Gram-positive and Gram-negative bacteria.[@CIT0029] The combination of amoxicillin and AgNP resulted in a synergistic effect against *E. coli*.[@CIT0018] Phenazine-1-carboxamide combined with silver nanoparticles synthetized by *Fusarium oxysporum* (AgNP~bio~) resulted in a synergistic effect against MRSA.[@CIT0012] Eugenol with AgNP~bio~ showed a synergistic effect against *Streptococcus agalactiae*.[@CIT0031] AgNP in combination with cinnamaldehyde exhibited a synergistic effect against spore-forming bacterial strains.[@CIT0032] A recent study demonstrated the antibacterial activity of oregano essential oil combined with AgNP~bio~. These combinations demonstrate antibacterial activity against multidrug-resistant bacteria.[@CIT0014] Besides, a recent report showed antifungal activity of simvastatin combined with AgNP~bio~ against toxigenic species of *Aspergillus*.[@CIT0033]

In the present study, we evaluated, for the first time, the antibacterial activity of simvastatin combined with AgNP~bio~ against reference and multidrug-resistant bacterial strains and analyzed the bacterial morphological alterations through electronic microscopy. This combination is under patent BR1020140323759 (INPI -- Brazil).

Materials And Methods {#S0002}
=====================

Simvastatin {#S0002-S2001}
-----------

Simvastatin was obtained commercially (Henan Topfond Pharmaceutical Co. Ltd, China) and dissolved in dimethyl sulfoxide (DMSO) 100% vv^−1^ at a stock concentration of 5 mg mL^−1^.

Synthesis Of The Silver Nanoparticles {#S0002-S2002}
-------------------------------------

AgNP~bio~ was obtained biologically by fungus-mediated synthesis as previously described.[@CIT0034] This methodology of AgNP~bio~ production has been patented (Patent, 2006, PI 0605681-4A2). The *F. oxysporum* strain 551 used was obtained from the culture collection of the Molecular Genetics Laboratory ESALQ-USP, Piracicaba-SP, Brazil. We cultured *F. oxysporum* in malt agar (Difco^®^) containing 0.5% yeast extract, 2% malt extract, 2% agar, and distilled water for 7 days at 28ºC. We then added 10 g of fungal biomass (previously washed) from the culture medium to 100 mL of sterile distilled water and incubated for 72 hrs at 28ºC. Subsequently, the supernatant was separated from the fungal biomass by vacuum filtration and AgNO~3~ (Sigma-Aldrich^®^) was added to the supernatant to a final concentration of 10 mM; the system solution was kept incubated at 28ºC in the absence of light until formation of AgNP~bio.~ Observation of AgNP~bio~ formation was performed visually and by absorptions until the formation of nanoparticles. We measured absorptions using ultraviolet-visible spectrophotometry (Varian Cary 50 Probe) to verify the formation of silver nanoparticles that presented surface plasmon resonance at 420 nm. After purification, the AgNP~bio~ was characterized.

Characterization Of The AgNP~bio~ And Simvastatin {#S0002-S2003}
-------------------------------------------------

Morphological and size of AgNP~bio~ was determined by photon correlation spectroscopy using ZetaSizer NanoZS (Malvern^®^), the same instrument was used to perform the zeta potential measurement and polydispersity index (PDI). Transmission Electron Microscopy (TEM) was performed to confirm morphological and size of AgNP~bio~. UV-vis was made to detect wavelength corresponding to AgNP~bio~. Size of simvastatin particles was analyzed using Dynamic Light Scattering (DLS).

Bacterial Strains {#S0002-S2004}
-----------------

Two reference methicillin-sensitive *St. aureus* (MSSA) strains (ATCC 25923 and ATCC 29213), two reference MRSA strains (MRSA N315 and MRSA BEC 9393), *E. coli* ATCC 25922, and extended-spectrum beta-lactamases *E. coli*-producing (ESBL 176) were used in this study. MRSA N315 strain was provided by Dr. Elsa Masae Mamizuka (Universidade de São Paulo, São Paulo-SP, Brazil) and BEC 9393 strain by Dr. Agnes Marie Sá Figueiredo (Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil). *E. coli* ESBL 176 strain was provided by Dra. Eliana Carolina Vespero (University Hospital -- HU, Universidade Estadual de Londrina, Londrina-PR, Brazil). Bacterial strains were stored in brain heart infusion (BHI) broth containing 20% (vv^−1^) glycerol and maintained at −80°C.

Antimicrobial Disk Susceptibility Test -- Disk Diffusion {#S0002-S2005}
--------------------------------------------------------

We performed the antimicrobial disk susceptibility test according to previously described procedures.[@CIT0035] Previously grown bacteria were suspended in saline according to 0.5 McFarland turbidity (corresponding to approximately 1 x 10^8^ CFU mL^−1^) and the bacterial suspension was inoculated on a plate with Muller-Hinton agar (MHA) using a cotton swab according to the Clinical and Laboratory Standards Institute.[@CIT0036] The disks containing 10 μL of simvastatin and AgNP~bio~ (corresponding to 0.115 mg and 169.86 mg, respectively) were placed on the surface of an inoculated agar plate. A negative control of DMSO was added to the test. The plates were incubated for 24 hrs at 37°C and the growth inhibition halo was measured.[@CIT0035]

Minimal Inhibitory Concentration Of Simvastatin And AgNP~bio~ {#S0002-S2006}
-------------------------------------------------------------

We determined minimal inhibitory concentration (MIC) by broth microdilution assay in 96-well microplates (Corning^®^) according to the Clinical and Laboratory Standards Institute guidance.[@CIT0037] In brief, we added different concentrations of simvastatin (from 0.015 mg mL^−1^ to 0.250 mg mL^−1^) and AgNP~bio~ (from 0.013 mg mL^−1^ to 0.212 mg mL^−1^) diluted in Mueller-Hinton broth (MHB). Bacteria were grown in MHA medium and suspended according to 0.5 McFarland as previously described. This bacterial suspension was diluted in MHB to a ratio of 1:100 and inoculated in 96-well microplates at a density of 5.0 × 10^5^ CFU mL^−1^ per well. We added DMSO as a negative control at equal concentrations (1.25 to 5% vv^−1^) to those used to dilute simvastatin. MHB medium was used for sterility control, and the positive control was performed by adding MHB medium and bacteria. The microplates were incubated at 37°C for 24 hrs. MIC was read visually and defined as the minimal concentration that inhibits bacterial growth visually according to turbidity. The assay was performed in triplicate.

Antibacterial Combination Assay (Checkerboard) {#S0002-S2007}
----------------------------------------------

After determining MIC of isolated compounds, we tested two compounds (AgNP~bio~ and simvastatin) together to evaluate the antibacterial interaction between them. The checkerboard assay was performed in 96-well microplates,[@CIT0038] where both compounds were diluted in MHB in combination, with concentrations ranging from 0.015.6 to 0.125 mg mL^−1^ and from 0.013 to 0.212 mg mL^−1^ for simvastatin and AgNP~bio~, respectively. Previously grown bacteria were suspended in saline according to 0.5 McFarland. This bacterial suspension was diluted in MHB to a ratio of 1:100 and inoculated in 96-well microplates at a density of 5.0 × 10^5^ CFU mL^−1^ per well. After 24 hrs of incubation at 37°C, the checkerboard was read visually and defined as minimal concentration that inhibits bacterial growth visually according to turbidity. The assay was performed in triplicate.

To qualify the interaction between both compounds, we calculated the fractional inhibitory concentration index (FICI) as previously described,[@CIT0039] using MIC combined of both compounds (MICc) and MIC alone of each compounds (MICa) the following equation: $$\documentclass[12pt]{minimal}
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We interpreted FICI according to the following index: ≤0.5, synergistic interaction effect; \>0.5 and ≤1.0, additive interaction effect; \>1 and \<4, indifferent; and ≥4, antagonistic interaction effect.

Time-Kill Curve Assay {#S0002-S2008}
---------------------

Time-kill curves were determined according to the National Committee for Clinical Laboratory Standards[@CIT0040] to evaluate the effect of simvastatin and AgNP~bio~ on growth kinetics of MRSA N315 and *E. coli* ESBL 176 producing. Bacterial strains were grown previously, and we prepared an inoculum corresponding to 0.5 on the McFarland scale and diluted in MHB to a ratio of 1:100. The compounds were tested alone and in combination, according to MIC and checkerboard assay, respectively, and compared with the bacterial positive control. At different time points of treatment and incubation (0, 2, 4, 7, 10, and 24 hrs) aliquots of bacterial culture were diluted and transferred to a plate with MHA to quantify the number of viable cells. After incubation of the MHA plate at 37ºC for 24 hrs, CFUs were counted and a time-kill curve was constructed. The assay was performed in triplicate.

Cytotoxicity Assay In Human Red Blood Cells {#S0002-S2009}
-------------------------------------------

Hemolytic assay of AgNP~bio~ and simvastatin was performed as Izumi et al 2012[@CIT0041] with modifications. Human red blood cells (HRBC) were taken from a healthy donor and approved by the human ethics committee (CAAE 47661115.0.0000.5231, No. 1.268.019 -- UEL). HRBC were collected in heparinized tubes (vacutainer), separated by centrifugation (5000 rpm, 4ºC, 5 mins) and diluted in 6% v v ^−1^ of phosphate-buffered saline (0.1 M PBS, pH 7,2). In a 96-well plate, 100 µL of HRBC 6% was added in 100 µL of AgNP~bio~ and simvastatin alone.

After 3 hrs of incubation at 37ºC, the supernatant was removed and read 550 nm. Triton-X 100 1% (Sigma-Aldrich) was used as a positive control for hemolysis. Concentration range tested was 0.015.6 to 0.125 mg mL^−1^ simvastatin and to AgNP~bio~ was 0.013 to 0.212 mg mL^−1^. Cytotoxic concentration in 50% (CC~50~) of HRBC was calculated for each compound through linear regression. Selectivity index (SI) was determined using following equation: SI=CC~50~/IC~50~.

Scanning Electron Microscopy (SEM) {#S0002-S2010}
----------------------------------

The MRSA N315 strain exposed to 4 situations was analyzed by SEM, as follows: (1) bacteria without antimicrobial treatment (control), (2) bacteria treated with 0.500 mg mL^−1^ of simvastatin, (3) bacteria treated with AgNP~bio~ at 0.212 mg mL^−1^, and (4) bacteria exposed to a combination of 0.125 mg mL^−1^ of simvastatin and AgNP~bio~ at 0.106 mg mL^−1^ respectively. Previously grown MRSA N315 strains were suspended according to 0.5 McFarland turbidity. A suspension containing approximately 10^8^ CFU mL^−1^ was prepared in MHB and all 4 samples were incubated at 37°C for 3 hrs. Next, the bacterial cells were obtained by centrifugation (5310 **×** g, for 5 mins at 10ºC) and washed and suspended with 0.1 M phosphate-buffered saline (PBS) at pH 7.4. 20 µL cell suspensions of MRSA N315 were spotted on glass slides previously coated with a thin layer of 10% poly-L-lysine. Afterwards, we fixed each slide containing MRSA N315 through immersion in 1 mL of 2% glutaraldehyde and 2% paraformaldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) solution for 12 hrs, followed by post-fixation in 1% OsO~4~ for 2 hrs.

Subsequently, the samples were dehydrated in graded ethanol series (70, 80, 90, and 100 GL) and critical point dried using CO~2~ (BALTEC CPD 030 Critical Point Dryer). The slides were taped onto stubs, coated with gold (BALTEC SDC 050 Sputter Coater), and finally examined using a FEI Quanta 200 scanning electron microscope.[@CIT0042]

Statistical Methods {#S0002-S2011}
-------------------

We evaluated the results by two-way ANOVA and standard deviation using R cran and considering p \< 0.05 significant. All samples were made in triplicate. Linear regression was performed to determine CC~50~ of cytotoxic assay.

Results {#S0003}
=======

Characterization Of The AgNP~bio~ And Simvastatin {#S0003-S2001}
-------------------------------------------------

The average AgNP~bio~ size was 77.68±33.95 nm and average zeta potential was −34.6±12.7 mV ([[Supplementary data](https://www.dovepress.com/get_supplementary_file.php?f=211756.pdf)]{.ul}). PDI for AgNP~bio~ was 0.182. TEM images show AgNP~bio~ average size of 50nm ([Figure 1](#F0001){ref-type="fig"}). Particle size of simvastatin was 110.8±46.8 nm. UV-Vis wavelength corresponding to AgNP~bio~ was 420 nm[@CIT0022] ([Figure 2](#F0002){ref-type="fig"}).Figure 1Characterization by transmission electron microscopy (TEM) of AgNP~bio~ synthesized by *Fusarium oxysporum* (300,000×).Figure 2UV-Vis spectrophotometry of nanoparticles synthetized by *Fusarium oxysporum.*

Antimicrobial Disk Susceptibility Test -- Disk Diffusion {#S0003-S2002}
--------------------------------------------------------

The antimicrobial disk susceptibility assay showed that AgNP~bio~ formed inhibition zones against MSSA ATCC 25923, *E. coli* ATCC 25922, and multidrug-resistant strains. The disk containing simvastatin showed no inhibition of either Gram-positive or Gram-negative bacteria, not forming inhibition zones ([Table 1](#T0001){ref-type="table"}).Table 1Results Of Antimicrobial Disk Susceptibility And Minimal Inhibitory Concentration (MIC), Checkerboard, And Fractional Inhibitory Concentration (FICI) For Bacterial StrainsBacterial strainInhibition Zone Size (mm)Minimal Inhibitory Concentration (MIC)MIC Of Simvastatin And AgNP~bio~ Combined (mg mL^−1^; mg mL^−1^)SimAgNP~bio~SimAgNP~bio~CombFICIMSSA ATCC 2592307.330.0620.2120.015;0.0520.5(S)MSSA ATCC 2921307.750.0620.2120.031;0.0520.75(A)MRSA N31507.330.0620.2120.015;0.0520.5(S)MRSA BEC9393080.2500.2120.031;0.1060.62(A)*Escherichia coli* ESBL 17609.33\>0.2500.1060.015;0.052\**E. coli* ATCC 2592208.33\>0.2500.1060.062;0.106\*[^1]

Minimal Inhibitory Concentration Of Simvastatin And AgNP~bio~ {#S0003-S2003}
-------------------------------------------------------------

Simvastatin only demonstrated antibacterial activity against the Gram-positive bacterial strains MSSA ATCC 25923, MSSA ATCC 29213, MRSA BEC 9393, and MRSA N315, with MIC values ranging from 0.062 mg mL^−1^ to 0.25 mg mL^−1^. AgNP~bio~ showed a broad spectrum of action, acting against Gram-positive and Gram-negative bacterial strains, with an MIC value of 0.212 mg mL^−1^ against MSSA ATCC 25923, MSSA ATCC 29213, MRSA N315, and MRSA BEC 9393, and 0.106 mg mL^−1^ against *E. coli* ATCC 25922 and *E. coli* ESBL 176 producing ([Table 1](#T0001){ref-type="table"}). Simvastatin and AgNP~bio~ presented MICs of 0.062 mg mL^−1^ and 0.212 mg mL^−1^, respectively, against MRSA N315. *E. coli* ESBL 176 demonstrated no susceptibility to simvastatin, whereas AgNP~bio~ was active against this strain at an MIC value of 0.106 mg mL^−1^. DMSO control not inhibited bacterial growth.

Antibacterial Combination Assay (Checkerboard) {#S0003-S2004}
----------------------------------------------

The results of the checkerboard assay ([Table 1](#T0001){ref-type="table"}) showed that there were synergistic and additive antibacterial effects between simvastatin and AgNP~bio~. The combination demonstrated potentiated antibacterial activity against MRSA N315 and MSSA ATCC 25923, decreasing the concentration used for antibacterial effect. The concentration was reduced to 75% when simvastatin and AgNP~bio~ were in combination.

Time-Kill Curve Assay {#S0003-S2005}
---------------------

The results showed that simvastatin, when used alone, had a bacteriostatic effect against MRSA N315 ([Figure 3](#F0003){ref-type="fig"}), while AgNP~bio~, at 24 hrs, had a bactericidal effect. Combination of AgNP~bio~ with simvastatin shows difference between treatments alone of AgNP~bio~ (p \< 0.05) e simvastatin (p \< 0.05) eliminate entire bacterial population.Figure 3Time-kill curves for methicillin-resistant *Staphylococcus aureus* N315. AgNP~bio~ treatment at a concentration of 212.33 mg mL^−1^; treatment with 0.062 mg mL^−1^ simvastatin; AgNP~bio~ and simvastatin in combination, at concentrations of 53.08 mg mL^−1^ and 0.015 mg mL^−1^ respectively. (**A**) ^a^Comparison of simvastatin with the combination; ^b^comparison of AgNP~bio~ with the combination; ^c^comparison of simvastatin with AgNP~bio~; ^d^treatments compared to control.

Afer 10 hrs of incubation, all cells of the bacterial population were eradicated by simvastatin and AgNP~bio~ combined (p \< 0.05), against N315 MRSA. In comparison, simvastatin when used alone against *E. coli* ESBL 176 not showed antibacterial activity ([Figure 4](#F0004){ref-type="fig"}). AgNP~bio~ was bactericidal in 24 hrs against MRSA N315 and decreased the concentration cells in 4 hrs. Simvastatin was bacteriostatic, and the combination was more effective than simvastatin used alone, showing bactericidal activity in 4 hrs.Figure 4Time-kill curves for extended-spectrum beta lactamases-producing *Escherichia coli* 176. AgNP~bio~ treatment at a concentration of 212.33 mg mL^−1^; treatment with 0.250 mg mL^−1^ simvastatin; AgNP~bio~ and simvastatin in combination, at concentrations of 106.16 mg mL^−1^ and 0.015 mg mL^−1^, respectively. ^a^Comparison of simvastatin with the combination; ^b^comparison of AgNP~bio~ with the combination; ^c^comparison of simvastatin with AgNP~bio~; ^d^treatments compared to control.

Cytotoxicity Assay In HRBC {#S0003-S2006}
--------------------------

Simvastatin showed a CC~50~ in HRBC in range of 0.260 mg mL^−1^. CC~50~ AgNP~bio~ was 9283.4 mg mL^−1^. CC~50~ of simvastatin and AgNP~bio~ was the concentration above MIC 0.260 mg mL^−1^ and 9.283.4 mg mL^−1^, respectively. SI was 4.193 for simvastatin and 43.789 for AgNP~bio~.

Scanning Electron Microscopy (SEM) {#S0003-S2007}
----------------------------------

SEM analysis showed that the untreated MRSA N315 sample presented a large number of smooth cells, an intact surface, and unaltered average size, with typical features unchanged in format, arrangement, and appearance as found in treated cells ([Figure 5A](#F0005){ref-type="fig"} and [B](#F0005){ref-type="fig"}). The MRSA N315 sample exposed to simvastatin treatment presented some cells with normal appearance, arrangement, and format, while others presented deformations; the micrographs demonstrated the formation of a large amorphous mass caused by destruction of the bacterial cells in the treatment with simvastatin ([Figure 5C](#F0005){ref-type="fig"} and [D](#F0005){ref-type="fig"}). The AgNP~bio~ treatment caused alterations in cell morphology, such as protrusions of numerous small bubbles a few nanometers in size; the metal nanoparticles also resulted in numerous lysed cells and cell debris ([Figure 5E](#F0005){ref-type="fig"} and [F](#F0005){ref-type="fig"}). Cells treated with a combination of simvastatin and AgNP~bio~ showed both types of alterations: formation of a large amorphous mass caused by simvastatin and a protrusion of numerous small bubbles caused by AgNP~bio~. It was possible to identify cell surface protrusions, amorphous mass, small bubbles, lysed cells, and cell debris, showing the interaction between the two compounds ([Figure 5G](#F0005){ref-type="fig"} and [H](#F0005){ref-type="fig"}).Figure 5Scanning electron microscopy (SEM) images of methicillin-resistant *Staphylococcus aureus* (MRSA) N315 after 3 hrs of incubation. (**A**) Negative control (not treated) (25,000×). (**B**) Positive control (50,000×). (**C**) Treatment with 0.050 mg mL^−1^ simvastatin (25,000×). (**D**) Treatment with 0.050 mg mL^−1^ of simvastatin (50,000×). (**E**) Treatment with 212.33 mg mL^−1^ of AgNP~bio~ (25,000×). (F) Treatment with 212.33 mg mL^−1^ of AgNP~bio~ (50,000×). (**G**) Treatment with 0.012 mg mL^−1^ of simvastatin and 106.16 mg mL^−1^ of AgNP~bio~ in combination (25,000×). (**H**) Treatment with 0.012 mg mL^−1^ of simvastatin and 106.16 mg.mL^−1^ of AgNP~bio~ in combination (50,000×).

Discussion {#S0004}
==========

Statins are used for treatment antihyperlipidemic effects in patients with high cholesterol by competitively inhibiting the enzyme HMG-CoA reductase, decreasing cholesterol biosynthesis.[@CIT0005] Simvastatin is also known to present pleiotropic effects, such as anti-inflammatory, antithrombotic, and antimicrobial effect.[@CIT0006]--[@CIT0008] and shows hepatocyte cytotoxicity.[@CIT0043] Therefore, the combination and consequent decrease in the concentrations of simvastatin have advantages in reducing cytotoxicity.

Results obtained by disk diffusion assay showed no inhibition by simvastatin in any bacteria tested. Antibacterial activity was demonstrated by broth microdilution assay, showing an inhibitory effect of simvastatin against MSSA and MRSA strains. Several studies have performed only disk or well diffusion into agar for evaluation of antimicrobial activity, mainly assay with nanoparticles, but some compounds do not diffuse into agar very well, other methods being recommended such as microdilution in broth and time-kill curves.[@CIT0022] Our results showed small halos (inhibition zones) for AgNP~bio~ and none for simvastatin, but high antibacterial activity in the broth microdilution and time-kill curves. This method can be performed as screening assay and other techniques are recommended for complete evaluation for antibacterial activity.

Several studies have shown that simvastatin has an antibacterial effect against *S. aureus* strains, with MIC ranging from 0.050 mg mL^−1^ to 0.300 mg mL−1.[@CIT0008],[@CIT0044]--[@CIT0046] Results obtained in the literature show that MIC values are similar to those obtained in our study. In general, MIC values are higher in MRSA than MSSA, although this was not observed in our study. The results obtained for simvastatin against *E. coli* (ESBL 176 and ATCC 25922) demonstrated no antibacterial effect. A recent study obtained the same results: simvastatin showed no antibacterial effect against Gram-negative bacteria.[@CIT0047] Structural differences between Gram-positive and Gram-negative bacteria could lead to the difference in the antibacterial activity of simvastatin. According to a previous study, statins have a bacteriostatic effect against *S. aureus* strains,[@CIT0046] and similar results were obtained in the present study, where simvastatin showed growth inhibition of the MRSA tested.

Our results demonstrated an inhibitory effect of AgNP~bio~ against *S. aureus* and *E. coli*. The broad spectrum of antibacterial activity of AgNP~bio~ could be due to different targets in bacteria cells such as DNA, vital enzymes, and cell membrane, structures present in both Gram-positive and Gram-negative bacteria.[@CIT0016] The same inhibitory effects against *S. aureus* and *E. coli* were reported in earlier studies.[@CIT0048],[@CIT0049] Our silver nanoparticles are biogenic (by *F. oxysporum*) with an average diameter of 77.68 ± 33.95 nm. AgNP~bio~ MIC values were 212.33 mg mL^−1^ for *S. aureus* and 106.16 mg mL^−1^ for *E. coli* strains, keeping the same MIC for more than one year (data not shown). MIC value was lower for *E. coli* than *S. aureus* strains, showing that the antibacterial effect of AgNP~bio~ was higher for *E. coli* strains (Gram-negative). Gram-positive and Gram-negative bacteria present differences in structure such as peptidoglycan (cell wall) and this difference may interfere in antibacterial activity in Gram-positive bacteria (peptidoglycan thicker). Other factors that influence the antibacterial activity of AgNP~bio~ are size, morphology, and coating of nanoparticles. AgNP~bio~ with smaller sizes are more efficient than nanoparticles of larger size.[@CIT0016],[@CIT0050],[@CIT0051]

Resistance to antimicrobials reduces the range of treatment options by increasing the cost and making it more difficult to eliminate microorganisms through enhanced severity of infections.[@CIT0001] Therefore, there is a necessity to discover new treatment options. Studies have recommended the combination of drugs as a strategy to control antimicrobial resistance.[@CIT0052],[@CIT0053] Studies involving synergism have been especially important for multidrug-resistant bacteria therapy.[@CIT0017],[@CIT0031] Therefore, there is a need to search for new antibiotics. Regarding the search for new treatments, in addition to the investigation of new drugs, combinations with AgNP and another compound such as amoxicillin,[@CIT0018] cinnamaldehyde,[@CIT0032] eugenol,[@CIT0031] oregano essential oil,[@CIT0014] and phenazine-1-carboxamide[@CIT0012] have demonstrated better antibacterial action when combined. Simvastatin when combined with AgNP~bio~ presents a new treatment option against infections caused mainly by *S. aureus* and *E. coli*. Our results showed that simvastatin when used alone has a bacteriostatic effect, not being as effective against bacteria. Although AgNP~bio~ has a bactericidal effect when used alone, bacterial resistance has been described.[@CIT0028] The use of the combination, in addition to improving activity, decreases the time of action and concentration, and minimizes the occurrence of resistance (lower dose). This combination has a greater effect than isolated drugs, establishing a new perspective for treating infections.

A recent study shows antifungal activity of the simvastatin combined with AgNP~bio~ synthetized by *F. oxysporum* against species of *Aspergillus*.[@CIT0033] This study reported, for the first time, combination of statins and nanoparticles against bacteria including multidrug-resistant bacteria strains. In the checkerboard test, the combination of simvastatin and AgNP~bio~ showed a synergistic effect against MSSA ATCC 25923 and MRSA N315, demonstrating that the combination decreased to 75% the concentration used to eliminate these bacteria. In addition, the combination of both compounds against MRSA BEC 9393 and MSSA ATCC 29213 presented an additive antibacterial effect, decreasing by 50% the concentration to eliminate these bacteria. Our results showed that simvastatin used in combination with AgNP~bio~ caused a 2-log decrease in the bacterial population at 4 hrs when used against MRSA. The MIC values decreased 4-fold for both, indicating a synergistic effect between the two compounds. When the combination was used, all bacteria were eliminated within 10 hrs, which was less than half the time observed for separate applications.

Studies have used AgNP~bio~ with other compounds, showing a synergistic interaction effect. The combination of AgNP~bio~ with phenazine-1-carboxylic caused a decrease in MIC.[@CIT0012] AgNP~bio~ in combination with eugenol showed a synergistic interaction effect against *S. agalactiae*.[@CIT0031] AgNP~bio~ combined with oregano essential oil demonstrated a synergistic and additive effect against multidrug-resistant bacterial strains.[@CIT0014] Simvastatin, when combined with AgNP~bio~, showed a synergistic effect against some strains of *S. aureus*, including MRSA. The synergic effect of the simvastatin with AgNP~bio~ decreased the inhibitory concentration to 4-fold for both compounds, also therapeutic concentration.

Another important aspect of this synergism is the toxicity of simvastatin and AgNP~bio~. Simvastatin has presented hepatotoxicity in humans.[@CIT0054] In relation to AgNP~bio~, there is also concern with the environment. Thus, our results showed that low concentrations of both compounds had a higher effect than alone (synergism).[@CIT0022] In HRBC cells, simvastatin shows a CC~50~ in concentration of 0.260 mg mL^−1^ and AgNP~bio~ CC~50~ of 9283.4 mg mL^−1^. Results of SI showed viable application in medical area.

There are no reports of SEM in the literature of bacteria treated with simvastatin. Our results showed morphological alteration in the bacterial cells similar to an amorphous mass. Through SEM, we observed cellular morphological alterations within a few hours of incubation with treatments of simvastatin, AgNP~bio,~ and a combination of both compounds. A previous study obtained images of samples treated with AgNP~bio~ showing a formation of protrusions on the surface of most cells. Studies have demonstrated that the cytoplasmic material is lost, suggesting that AgNP~bio~ interferes with the permeability of the bacterial cell membrane.[@CIT0014],[@CIT0031],[@CIT0055] In our study, treatment with AgNP~bio~ caused the formation of protrusions of numerous small bubbles a few nanometers in size, numerous lysed cells, and cell debris, suggesting the similar mechanism of action. In SEM, the combination of AgNP~bio~ and simvastatin showed cellular morphological alterations characteristic of both compounds. Studies using the combination of AgNP~bio~ and other compounds obtained similar results.[@CIT0014],[@CIT0031]

Conclusion {#S0005}
==========

In conclusion, our study showed synergism interactions effect between simvastatin and AgNP~bio~ synthetized by *F. oxysporum*, on antibacterial activity against a MRSA N315. These data suggest that the combination of these compounds is a possible treatment option for fighting resistant bacterial infections. In addition, it was possible to observe different cell changes under simvastatin and AgNP~bio~ by SEM.

The combination of simvastatin and AgNP~bio~ has potential to be applied in industry (pharmaceutical) and hospitals (impregnated in materials and treatment of wounds and burns infections).

Mechanism of action and physical-chemical compatibility of the combination of compounds are the next steps of our group.
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[^1]: **Notes:** MIC: minimal inhibitory concentration; FICI: fractional inhibitory concentration index was calculated as previously described[@CIT0036] and we interpreted it as follows: FICI ≤0.5, synergistic interaction effect; \>0.5--1.0, additive interaction effect; \>1 and \<4, indifferent; ≥4, antagonistic interaction effect. SIM: simvastatin; AgNP~bio~: silver nanoparticles obtained by *Fusarium oxysporum*, Comb: combination of simvastatin and AgNP~bio~. Methicillin-resistant *Staphylococcus aureus* (MRSA); Methicillin-sensitive *Staphylococcus aureus* (MSSA); American Types Culture Collection (ATCC); Extended-Spectrum Beta-lactamase (ESBL). FICI: (S): synergistic interaction effect; (A): additive interaction effect; \*FICI was not calculated.
